A toxin in the bacteria that’s one of the most common causes of foodborne illness accelerates the spread of colorectal tumours to other parts of the body, a study led by UF Health Cancer Center researchers and international collaborators has found.

The findings, published in the journal Cell Host & Microbe, could pave the way for new tools to detect metastatic colorectal cancer early and could ultimately help determine patients who need more aggressive treatments.

“This work contributes to a new understanding of how bacterial toxins promote colorectal metastasis, opening novel screening approaches to predict at-risk patients,” said Christian Jobin, Ph.D., the Gatorade Distinguished Professor of Medicine in the UF College of Medicine who oversaw the new research, which his former postdoc Zhen He, M.D., began in Jobin’s lab.

The intestinal microbiota is the collection of microorganisms that live in the gut. These microorganisms are known to play a wide-ranging role in health, from digestion to regulation of the immune system. They also influence the development and spread of several types of cancer, including colorectal.

Campylobacter jejuni (C. jejuni) is a bacterium that causes more than 2 million cases of diarrheal-related illness each year in the United States. Some C. jejuni species have a toxin called cytolethal distending toxin, or CDT. Jobin, co-leader of the UF Health Cancer Center’s Immuno-Oncology and Microbiome research program, and his lab previously showed this toxin was essential to causing colorectal cancer in mice.

In the new study, the team set out to find how the bacteria affect the spread of cancer. Colorectal cancer is the second-leading cause of cancer death in the United States, but when it’s caught early, before it has spread, the five-year relative survival rate is about 90%. Metastases, or secondary growths formed away from the initial cancer site, are the primary cause of death from cancer, and treatment options for these patients remain limited.

Jobin’s team first compared the presence of C. jejuni in tissues from 34 patients with primary colorectal cancer who ended up developing metastasis with 37 patients who did not develop metastasis within a three-year follow-up period.

They found a significant presence of the bacteria in the patients with metastasis. Notably, patients with detectable levels of the bacteria had a significantly poorer outlook than those without. The team confirmed these findings in large national data sets of tumour samples.

“These findings confirmed that CDT is essential for the bacteria’s role in promoting cancer spread,” Jobin said. “When bacteria that produce CDT move to tumours outside the gut, it appears to accelerate the spread of these tumours.”

Using laboratory mice with metastatic lung and liver tumours, human colorectal cancer tissue, and 3D colorectal cancer tumour models made from patient cells, the researchers showed how the bacterial toxin promoted the spread of cancer. They found CDT led to an increased expression of several types of enzymes and activated a type of signalling in cancer cells associated with metastasis.

Several clinical trials are testing drugs that aim to interfere with that cell-signalling pathway, meaning the findings may guide the development of new therapies, the researchers said.

The researchers also recovered live bacteria from tumours outside the gut, suggesting the tumours created an environment that was friendly to their growth. More research is needed to understand how the bacteria migrated to tumour sites and how the toxin activates the signalling pathways.

Raad Gharaibeh, Ph.D., a research associate professor in the Division of Gastroenterology, Hepatology & Nutrition in the UF College of Medicine and director of microbial genomics at the UF Health Cancer Center, was also a co-author of the study.

Source: University of Florida